Validación de la metodología para análisis de residuos de plaguicidas en agua para consumo humano

Debido a que los plaguicidas ocupan un lugar importante dentro de las sustancias químicas a las que el hombre esta expuesto, y frente a la necesidad de que los resultados obtenidos sean confiables, el objetivo de este trabajo consiste en la validación de la metodología analítica, basada en el método de Environmental Protection Agency (EPA) 505 revision 2.1 (1995): Analysis of organohalide Pesticide and commercial polychlorinated biphenyl (PCB) products in water by microextraction and gas chromatography, utilizando como valores de referencia los establecidos por el Código Alimentario Argentino, siguiendo los lineamientos de la norma de calidad ISO17025 :2005. Para la extracción de los plaguicidas se utiliza la extracción liquido-liquido con hexano y posterior identificación y cuantificación por cromatografía de gases. El método presenta muy buena sensibilidad con límites de detección de 0,003 a 0,3 ?g/L y de cuantificación de 0,01 a 0,9 ?g/L. En cuanto a la precisión del método medida como desviación estándar relativa es menor al 20% para todos los compuestos analizados. El método muestra una excelente linealidad en el rango de trabajo establecido, con coeficientes de determinación mayores a 0,995

Vigilancia tecnológica : análisis de normativas, propuesta metodológica e implementación práctica en una industria PyME argentina

Resumen: La Vigilancia Tecnológica es una herramienta basada en observar el entorno y el estado de la técnica actualizada, para luego filtrar y analizar información que posteriormente será utilizada para tomar decisiones estratégicas de negocios. El presente estudio está orientado a analizar diferentes normas de origen nacional e internacional, realizar una propuesta metodológica y aplicarla a una industria pyme nacional del sector metalmecánico agroindustrial, con el objeto de mejorar su competitividad, demostrar resultados y ser de referencia hacia otras empresas que deseen implementar estas herramientas, sean pymes o grandes empresas tanto de manufactura como de servicios.Abstract: Technological Vigilance is a tool based on watching the environment and the updated state of the art, to then filter and analyze information that will later be used to make strategic business decisions. The present study is oriented to analyze different national and international standards, make a methodological proposal and apply it to a national SME industry of the agro-industrial metalworking sector, in order to improve its competitiveness, demonstrate results and be of reference to other companies that wish to implement these tools, be they SMEs or large companies of both manufacturing and services

An international expanded-access programme of Everolimus : Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

BACKGROUND AND OBJECTIVES: The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC. PATIENTS AND METHODS: REACT (Clinicaltrials.gov: NCT00655252) was a global, open-label, expanded-access programme in patients with mRCC who were intolerant of, or who had progressed on or after stopping treatment with, any available VEGFr-TKI therapy. Patients received everolimus 10mg once daily, with dose and schedule modifications allowed for toxicity. Patients were closely monitored for the development of serious and grades 3/4 adverse events (AEs). Response was assessed by RECIST every 3months for the first year and every 6months thereafter. RESULTS: A total of 1367 patients were enroled. Safety findings and tumour responses were consistent with those observed in RECORD-1, with no new safety issues identified. The most commonly reported serious AEs were dyspnoea (5.0%), pneumonia (4.7%) and anaemia (4.1%), and the most commonly reported grades 3/4 AEs were anaemia (13.4%), fatigue (6.7%) and dyspnoea (6.5%). Best overall response was stable disease in 51.6% and partial response in 1.7% of patients. Median everolimus treatment duration was 14weeks. CONCLUSION: Everolimus is well tolerated in patients with mRCC and demonstrates a favourable risk-benefit ratio